Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULARStandard

ZYPREXA RELPREVV

OLANZAPINE PAMOATE

Standard Dose
EQ 210MG BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ZYPREXA RELPREVV is listed in Drugs@FDA under application 022173 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient OLANZAPINE PAMOATE Form and strength SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - EQ 210MG BASE/VIAL Sponsor CHEPLAPHARM Submission history Latest submission status date: 2026-01-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZYPREXA RELPREVV is listed in Drugs@FDA under application 022173 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient OLANZAPINE PAMOATE Form and strength SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - EQ 210MG BASE/VIAL Sponsor CHEPLAPHARM Submission history Latest submission status date: 2026-01-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.